Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · Real-Time Price · USD
1.270
-0.070 (-5.22%)
At close: Apr 1, 2025, 4:00 PM
1.261
-0.009 (-0.73%)
After-hours: Apr 1, 2025, 4:02 PM EDT
SONN Employees
Sonnet BioTherapeutics Holdings had 13 employees as of September 30, 2024. The number of employees increased by 1 or 8.33% compared to the previous year.
Employees
13
Change (1Y)
1
Growth (1Y)
8.33%
Revenue / Employee
$76,923
Profits / Employee
-$725,341
Market Cap
3.89M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SONN News
- 9 hours ago - Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - GlobeNewsWire
- 6 days ago - Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas - GlobeNewsWire
- 13 days ago - Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein - GlobeNewsWire
- 21 days ago - Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 4 weeks ago - Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - GlobeNewsWire
- 5 weeks ago - Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates - GlobeNewsWire
- 6 weeks ago - Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference - GlobeNewsWire
- 6 weeks ago - Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer - GlobeNewsWire